logo
Share SHARE
FONT-SIZE Plus   Neg

VIVUS Says FDA Extends Qnexa PDUFA Date

VIVUS Inc. (VVUS: Quote) said Monday that the U.S. Food and Drug Administration has extended the Prescription Drug User Fee Act date for its review of the Qnexa New Drug Application by three months from April 17 to July 17, 2012.

On April 4, following the FDA's request, VIVUS submitted the Qnexa Risk Evaluation and Mitigation Strategy, which was considered a major amendment to the NDA. The submission consisted of proposed REMS materials.

Since the receipt date was within three months of the user fee goal date, the FDA is extending the Prescription Drug User Fee Act date by three months to provide time for a full review of the submission, the company noted.

The Qnexa NDA seeks approval for the treatment of obesity, including weight loss and maintenance of weight loss for obese patients with weight-related co-morbidities such as hypertension, type 2 diabetes or dyslipidemia.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Diversified media and entertainment conglomerate Walt Disney Co. reported Tuesday a profit for the second quarter that grew 10 percent from last year, helped by strong performance at cable networks, parks and resorts as well as sales of Frozen merch. Both adjusted earnings per share and quarterly revenues topped analysts' expectations. Panera has banned more than 150 artificial ingredients from its food, and will remove all traces of the ingredients from its menu by 2016, the company confirmed Tuesday. Customers want a healthier menu, according to CEO Ron Shaich, who spoke with numerous media outlets about the changes. "We are... German department store operator Metro AG reported Tuesday a loss for the second quarter that widened from last year, despite sales growth, hurt by goodwill impairment at Real Germany. The company also confirmed its outlook for financial year 2014/15.
comments powered by Disqus
RELATED NEWS
Trade VVUS now with 
Follow RTT